Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease

CompletedOBSERVATIONAL
Enrollment

79

Participants

Timeline

Start Date

August 31, 2017

Primary Completion Date

November 30, 2022

Study Completion Date

November 5, 2024

Conditions
Crohn's DiseaseUlcerative ColitisHealthy Controls
Interventions
OTHER

The IBD group was divided into 2 subgroups: with or without anti-TNF antibody use

This observational study enrolled women with IBD, and some of them were receiving a treatment with anti-TNF monoclonal antibody, which was prescribed by their responsible prescribers at a standard dose and dosing interval.

Trial Locations (2)

M5G 1X5

Mount Sinai Hospital, Toronto

M5G 1X8

The Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

MOUNT SINAI HOSPITAL

OTHER

collaborator

Crohn's and Colitis Foundation

OTHER

lead

The Hospital for Sick Children

OTHER

NCT03397108 - Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease | Biotech Hunter | Biotech Hunter